Merrill puts New River at buy

New River Pharmaceuticals Inc. was reiterated at a buy rating by Merrill Lynch analyst David Munno on expectations that the company's news flow will increase in the next three to four months, with significant data presentations in June and maybe July. Merrill expects that NRP104 may be approved by the end of the year, likely after the Oct. 6 PDUFA date. New River remains a top pick in biotech for the analyst. Shares of the Radford, Va., pharmaceutical company were down 81 cents, or 2.38%, at $33.19 on volume of 177,690 shares versus the three-month running average of 218,192 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.